CRP and COVID-19: Using tocilizumab might also affect biochemistry indicators (lowered C-reactive protein and ferritin, increased lymphocyte count).<h4>Conclusion</h4>These current bodies of evidence could indicate that early use of tocilizumab was associated with lower mortality in adult patients with COVID-19.